查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098949

癌症輔助治療藥物市場－全球市場預測（2026-2032年）

Cancer Supportive Care Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症支持治療藥物市場將成長至 2.4697 億美元，複合年成長率為 7.00%。

主要市場統計數據
基準年 2025 1.5379億美元
預計年份：2026年 1.6403億美元
預測年份：2032年 2.4697億美元
複合年成長率 (%) 7.00%

支持性癌症治療是預防、減輕或控制癌症及其治療（包括化療、免疫療法、放射線治療、標靶治療和幹細胞移植）相關副作用的重要手段。這些藥物能夠滿足患者重要的臨床需求，例如化療引起的噁心嘔吐、嗜中性白血球低下症疼痛、嗜中性白血球減少症、貧血、感染風險、骨轉移相關併發症、黏膜炎、惡病質、血小板減少性疾病以及治療相關的消化器官系統和皮膚類毒性。隨著癌症治療日益個人化和強化，支持性癌症治療已從輔助服務轉變為多學科癌症診療的核心要素。其臨床目標不再局限於緩解症狀，還包括維持治療強度、減少不必要的住院治療、提高抗癌藥物治療方案的依從性、改善患者報告結局，以及在整個癌症治療過程中維持和提高患者的生活品質。癌症發生率上升、人口老化、癌症生存期延長、全身性治療的普及以及免疫腫瘤學的推廣，都增加了對實證支持治療的需求。監管機構、腫瘤學會和醫療保健系統日益重視基於指南的症狀管理、合理使用抗生素、降低鴉片類藥物風險、推廣生物相似藥以及在臨床實踐中進行安全監測。這些變化導致腫瘤治療領域對止吐藥、造血生長因子、止痛藥、骨骼調節劑、鐵劑、皮質類固醇、抗真菌藥物、抗真菌藥、止瀉藥、食慾促效劑和其他支持治療藥物的需求增加。生物相似藥、口服製劑、長效注射劑、支持用藥依從性的數位化工具、藥物藥物基因體學以及整合式安寧療護模式也對市場競爭格局和臨床環境產生影響。對於參與藥物研發、癌症醫療服務、保險公司和分銷網路的相關人員，癌症支持治療藥物已成為一個具有戰略意義的重要類別，它與癌症治療的連續性、病人安全和醫療保健系統的效率直接相關。

癌症輔助治療藥物領域的變革性變化

隨著癌症治療向長期聯合治療、門診給藥和以生存期為中心的管理模式轉變，癌症支持治療藥物領域正在經歷結構性變革。現代癌症治療正在改變藥物的毒性特徵，並產生除傳統化療併發症之外的新的支持性治療需求。免疫查核點抑制劑可引起免疫相關不利事件，需要使用皮質類固醇或免疫抑制劑治療；而分子標靶療法和抗體藥物偶聯物（ADC）則與皮膚、胃腸道、血液系統、眼部和呼吸系統毒性相關，需要積極介入。同時，止吐保護、嗜中性白血球減少嗜中性白血球低下症預防、癌症疼痛管理和骨骼健康維護等傳統需求仍然是臨床實踐的核心挑戰。一個重要的轉變是，越來越依賴與既定腫瘤支持治療指引一致的實證臨床路徑。這些途徑規範了5-HT3受體拮抗劑、NK1受體拮抗劑、集落刺激因子、促紅血球生成因子（按需使用）、雙磷酸鹽、RANK配體抑制劑以及在特定風險情況下預防性使用抗生素的使用。另一個顯著的變化是生物相似藥在腫瘤支持治療的應用範圍擴大，尤其是在造血生長因子領域。這提高了藥物清單的柔軟性，並更加重視在不降低安全性、純度和療效監管標準的前提下，實現更具成本效益的聯合用藥。此外，透過門診輸液中心、居家癌症支援、與專科藥房的合作、遠距醫療症狀分診以及口服抗癌藥物依從性計劃，患者獲得醫療服務的便利性也得到了提升。保險公司和醫療機構正日益將可避免的急診就診、因嗜中性白血球低下症導致的住院、無法控制的噁心、鴉片類藥物相關安全事件以及治療中斷等情況作為支持性護理的績效指標。這些變化促使製藥公司優先考慮能夠證明藥物具有差異化安全性、易於給藥、與複雜腫瘤治療方案相兼容以及對治療依從性和以患者為中心的療效具有可衡量影響的證據。

人工智慧在癌症支持治療的累積影響

人工智慧正開始影響癌症輔助治療藥物，透過改善風險預測、毒性監測、治療個人化以及提升癌症治療各環節的運作效率，為癌症治療帶來正面影響。人工智慧模型可以分析電子健康記錄、實驗室指標、治療方案、共病、既往毒性、基因組資訊以及患者報告結局，從而識別出嗜中性白血球低下症、化療引起的噁心嘔吐、鴉片類藥物相關併發症、免疫相關不利事件、營養不良、脫水、感染疾病或非計劃住院等高風險患者。經過適當檢驗並合理整合後，這些工具可以支持早期療育，例如早期使用止吐藥、生長因子、最佳化鎮痛方案、預防性使用抗生素、補液或向專科醫生報告。此外，人工智慧還能透過偵測來自真實世界數據、自發性不利事件報告、保險理賠資料集和臨床記錄中的安全訊號，為加強藥物警戒做出貢獻。自然語言處理可以幫助識別一些通常難以準確編碼的症狀，例如疲勞、黏膜炎的嚴重程度、食慾不振、神經病變疼痛和功能障礙。在藥物研發領域，人工智慧可以支援臨床試驗設計、合格篩檢、毒性叢集、生物標記發現以及癌症支持治療的療效比較研究。在臨床實踐中，預測分析可以幫助輸液中心預測支持治療藥物的需求，減少治療延誤，最佳化庫存，並調整專科藥房的配藥。然而，人工智慧的累積效應取決於資料品質、模型的透明度和公平性、臨床醫生的監督、隱私保護以及是否符合用於支援醫療決策的軟體的監管要求。人工智慧不會取代臨床判斷；相反，它可以透過幫助腫瘤團隊早期識別風險、規範基於指南的干預措施以及持續監測治療結果，來增強精準的支持治療。隨著醫療系統中報銷和品質評估與症狀管理和可避免的急性護理的使用越來越相關，人工智慧驅動的腫瘤支持護理工作流程正在成為高績效癌症計畫的實用差異化因素。

癌症輔助治療藥物的關鍵區域性見解。

在亞太地區，癌症治療基礎設施的擴建、癌症篩檢率的提高、人口老化以及系統性癌症治療的普及，推動了對止吐藥、造血生長因子、鎮痛藥、骨標靶治療、抗生素和營養支持的需求，從而促使人們更加關注癌症支持治療。該地區情況極為多樣化。先進的醫療保健系統正在加速推進基於規範的支持治療和數位化症狀監測，而新興市場則專注於基本藥物的可近性、可負擔性和供應。在北美，成熟的癌症治療網路、指南的廣泛應用、強大的專科藥房功能以及完善的報銷機制，都支持支持治療藥物的廣泛使用，尤其是在門診和社區癌症治療機構。臨床重點包括減少化療相關的住院治療、安全管理癌症疼痛、儘早啟動安寧療護、最佳化生物相似藥的使用。在拉丁美洲，公共癌症計畫、私營部門的治療管道以及地方癌症控制舉措正在加強癌症支持治療。然而，報銷體系、藥物可近性和診斷能力方面的區域差異仍影響著實施。在歐洲，健全的臨床指引框架、藥物安全監測系統、醫療技術評估流程和生物相似藥計畫正在塑造支持性治療方案，並日益關注以價值觀為導向的腫瘤治療、存活率以及各國公平的醫療服務取得。在中東，對腫瘤中心、國家癌症策略和先進治療能力的投資正在不斷推進，標準化支持性治療方案、疼痛管理、感染預防和治療依從性支持的重要性日益凸顯。在非洲，由於癌症負擔日益加重、許多地區癌症診斷已發展到晚期、癌症醫療專業人員短缺以及基本藥物取得方面的不平等，對癌症支持性治療的需求極為迫切。優先事項包括加強安寧療護、改善鎮痛藥和止吐藥的供應鏈、擴大感染控制以及將支持性治療納入國家癌症控制計劃。在所有地區，永續發展的機會都與可負擔性、監管協調、臨床醫生教育、真實世界數據 (REW) 生成以及以患者為中心的醫療保健服務模式密切相關。

來自全球醫療保健聯盟領先團體的見解

在東協，支持性癌症治療正透過腫瘤服務的擴展、公共醫療保險體系的改革以及區域層面為改善基本癌症治療可及性所做的努力而不斷推進；然而，都市區癌症中心與服務不足地區之間仍然存在差距。需求與化療、止吐方案等支持性治療、感染預防、疼痛緩解以及生技藥品和生物相似藥的可及性密切相關。海灣合作理事會（GCC）成員國擁有專業的癌症治療基礎設施、現代化的醫療保健系統以及對國家癌症策略的大量投資，這為基於方案的支持性治療、先進的靜脈輸液服務和數位化病患監測創造了有利條件。歐盟高度重視藥品安全、藥品安全監測、生物相似藥的可靠性、衛生技術評估以及跨境政策協調，為引入和改善循證支持性癌症治療提供了至關重要的環境。金磚國家面臨龐大的患者群體、不斷擴大的癌症治療能力、國內藥品生產能力以及嚴峻的可及性挑戰，因此在藥品可負擔性、本地化生產、學名藥和生物類似藥的使用以及基本藥物的分配等方面，政策制定者尤為關注。七國集團（G7）國家通常擁有先進的癌症治療體系、較高的臨床指南採納率、健全的法律規範以及強大的真實世界證據（RWE）收集能力，這為在化療、免疫療法、放射線治療和康復治療中更有效地使用輔助治療藥物提供了支持。北約成員國與北美和歐洲的高所得國家癌症治療體系存在顯著的重疊，但其報銷和採購環境也各不相同，因此，對於癌症輔助治療藥物而言，供應的穩定性、合理使用抗生素以及標準化的緊急應變系統都面臨著至關重要的挑戰。在這些國家集團中，政策重點日益趨於一致，即提高患者的生活品質、確保癌症治療的連續性、減少意外急診、安全使用鴉片類藥物和抗生素，以及以經濟有效的方式獲得高品質的輔助治療藥物。

各國癌症支持治療藥物的關鍵訊息

在美國，高度發展的癌症支持性治療體係由臨床路徑、專科藥房網路、保險公司管理的准入機制、門診癌症治療、生物類似藥的引入以及對避免急診就診和住院的高度重視所塑造。在加拿大，公平的醫療服務取得透過省級癌症治療體系、循證處方藥清單、綜合安寧療護以及支持性治療藥物的保險覆蓋決策來優先保障。在墨西哥，癌症治療的覆蓋範圍正在擴大，同時努力解決公共和私人保險覆蓋範圍的差異，其中止吐藥、鎮痛藥、抗生素和生長因子的可負擔性和穩定供應是核心考慮因素。在巴西，公共和私人醫療系統對癌症治療的需求都很高，支持性治療的需求與化療、疼痛管理、感染控制以及區域醫療保健差異密切相關。在英國，公共醫療體系強調基於指引的支持性癌症治療、早期安寧療護、藥物最佳化以及對臨床價值的系統性評估。在德國，先進的癌症治療基礎設施、健全的醫院和門診醫療網路以及循證支持治療的廣泛應用，都得到了嚴格的監管和報銷標準的支撐。在法國，重點在於癌症治療品質、藥物安全監測、支持治療的整合以及以病人為中心的癌症治療路徑。俄羅斯地域遼闊，面臨廣泛的支持治療需求，其政策重點在於國內生產、腫瘤學現代化以及獲得必要的癌症治療。義大利和西班牙擁有完善的腫瘤治療體系，支持治療與倖存者護理、症狀管理、生物相似藥的使用以及區域報銷框架的聯繫日益緊密。在中國，癌症治療體係正在快速發展，透過監管改革和醫保報銷制度的修訂，提高了藥物的可近性，隨著系統性癌症治療的普及，支持治療藥物的使用也不斷增加。印度的癌症治療環境龐大且複雜，經濟負擔、學名藥的可近性、安寧療護的可近性以及都市區差異都對癌症支持治療的實踐產生顯著影響。日本擁有先進的癌症治療基礎設施，且人口老化嚴重，因此其重點在於止吐管理、嗜中性白血球低下症預防、疼痛管理和安全監測。澳洲透過國家癌症政策、保險報銷機制和綜合腫瘤服務，支持實證支持治療。韓國則透過結合先進的癌症篩檢、現代化的治療中心、數位醫療的應用以及在臨床實踐中積極實施支持治療，來改善治療的連續性和患者預後。

為行業領導者提供的實用建議

產業領導者應優先進行證據收集工作，證明癌症支持治療藥物如何嗜中性白血球低下症，包括減少發燒性嗜中性球減少症、降低難治性噁心嘔吐的發生率、減少治療延誤、改善疼痛管理、減少骨骼相關併發症、遵守用藥以及減少非計劃急診就診次數。產品策略應強調差異化的耐受性、簡化的給藥方式、與聯合治療的兼容性以及在門診、家庭和專科藥房模式下的便利性。相關人員應加強與腫瘤臨床指南的銜接，並投資於真實世界數據（REW）項目，以收集不同患者群體中的患者報告結局、用藥依從率、住院模式和安全性訊號。藥物可及性策略應反映各地區在基本藥物報銷、採購和供應方面的差異，尤其關注價格合理的製劑、生物相似藥、學名藥和具有韌性的供應鏈。在與腫瘤醫療服務提供者合作時，重點應放在方案實施、臨床醫生培訓、護士主導的症狀管理、藥劑師主導的藥物審查支持以及支持用藥依從性的數位化工具上。此外，企業和醫療機構需要透過確保資料互通性、倫理模型檢驗、隱私合規性和透明的臨床管治，為人工智慧驅動的支援性護理做好準備。在高成長地區和醫療資源有限的環境中，最有效的方法包括提高基本支持性護理藥物的可近性、支持安寧療護培訓、根據需要擴展低溫運輸和配送能力，以及創建反映實際腫瘤診療實踐的區域性證據。在所有市場，領導者都應將支持性照護定位為支撐癌症治療品質、病患體驗和醫療系統效率的策略支柱，而非次要類別。

調查方法

本執行摘要採用結構化的二級研究途徑撰寫，重點檢驗的、資料支援的資訊來源，並對權威的醫療保健文獻進行交叉驗證。該調查方法強調檢驗與腫瘤臨床指南、監管出版刊物、公共衛生癌症控制資源、同行評審的醫學文獻、藥物安全監測框架、衛生技術評估 (HTA) 文件、癌症負擔、治療毒性、藥物可及性以及腫瘤支持治療實踐相關的全球公認的醫療保健資料集。研究過程包括繪製癌症支持治療中使用的關鍵藥物類別圖譜，評估化療、化療、放射線治療、標靶治療和安寧療護等臨床應用案例，以及評估區域政策和醫療保健服務趨勢。對研究結果的整合不依賴市場規模、市場佔有率或預測。研究考慮了指南採納、報銷結構、可及性障礙、生物相似藥計劃、融入臨床工作流程、安全監測以及以患者為中心的結果優先排序等定性指標。我們從醫療基礎設施、癌症治療可及性、監管成熟度、藥物可及性以及不斷發展的護理標準等方面，解讀區域、群體和國家層面的具體見解。為確保可信度，所有論點均基於已確立的臨床和政策趨勢，而非投機性的商業性預測。這種方法能夠為在複雜且快速發展的腫瘤學生態系統中尋求策略方向的相關人員提供最佳化且基於實證醫學的癌症支持治療視角。

結論

隨著醫療體系致力於提高治療耐受性、維持抗癌治療的連續性、減少可預防的併發症並提升癌症患者的生活品質，支持性治療藥物在腫瘤學中扮演著日益重要的角色。這一類別涵蓋了多種藥物，用於治療噁心嘔吐、中性粒細胞減少症、貧血、疼痛、感染疾病、嗜中性白血球低下症併發症、營養缺乏、胃腸道毒性以及免疫介導的不利事件。變革性趨勢包括基於指南的診療路徑、生物相似藥的引入、門診和居家腫瘤支持、真實世界數據（REW）的生成，以及人工智慧（AI）在預測性風險管理和藥物警戒中的新應用。區域和國家層面的趨勢表明，先進的腫瘤治療體係正透過品質指標和數位化整合來完善支持性治療，而新興經濟體和資源匱乏地區則繼續優先考慮獲得必要的支持性治療藥物、確保藥物的可及性、加強醫護人員培訓以及發展安寧療護體系。對於行業領導者而言，成功的關鍵在於將臨床可信度與切實可行的准入策略、以患者為中心的循證醫學證據、穩健的供應鏈以及技術驅動的醫療協作相結合。隨著癌症治療的不斷發展，支持性治療藥物對於更安全、更有效、更人性化的腫瘤治療實踐仍至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：癌症支持治療市場：依藥物類別分類

  • 止吐藥
    • 5-HT3拮抗劑
    • NK1拮抗劑
    • Olanzapine
  • 骨調節劑
    • 雙磷酸鹽類藥物
    • RANKL抑制劑
  • 造血因子
    • 紅血球生成促進劑
      • Darbepoetin
      • 促紅素
    • 骨髓保護劑
    • 血小板生成素受體促效劑
  • 疼痛管理藥物
    • 非鴉片類藥物
      • 乙醯胺酚
      • 輔助止痛藥
      • 非類固醇消炎劑（NSAIDs）
    • 鴉片類藥物

第8章：癌症支持治療市場：依癌症類型分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 骨髓發育不良症候群
  • 固體癌
    • 乳癌
    • 結腸癌
    • 胃腸道癌症
    • 頭頸癌
    • 肺癌
    • 卵巢癌
    • 攝護腺癌

第9章：癌症輔助治療藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 直腸
  • 皮下
  • 外用
  • 經皮給藥

第10章：癌症支持療法市場：以原廠藥類型分類

  • 生物相似藥
  • 品牌
  • 非專利的

第11章：癌症輔助治療藥物市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第12章：癌症輔助治療藥物市場：依適應症分類

  • 與骨轉移相關的事件
  • 惡病質和食慾不振
  • 癌症疼痛
  • 化療引起的噁心和嘔吐（CINV）
    • 急性化療引起的噁心嘔吐
    • 難治性/治療抵抗性化學治療引起的噁心嘔吐
    • 延遲性 CINV
  • 腹瀉
  • 黏膜炎和口腔炎
  • 骨髓抑制
    • 化療引起的貧血
    • 化療引起的嗜中性白血球低下症

第13章：癌症支持治療藥物市場：依護理環境分類

  • 住院治療
  • 門診

第14章：癌症輔助治療藥物市場：依通路分類

  • 醫院藥房
  • 郵購藥局及網路藥局
  • 零售藥房
  • 專科藥房

第15章：癌症支持治療市場：依最終用戶分類

  • 門診手術中心
  • 居家照護
  • 醫院
  • 癌症治療診所及靜脈輸液治療中心

第16章 癌症輔助治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第17章：癌症支持治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 癌症輔助治療藥物市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 日本
  • 印度
  • 英國
  • 加拿大
  • 俄羅斯
  • 巴西
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第20章：公司簡介

  • Abbott Laboratories
  • Acacia Pharma Group Plc
  • Accord Healthcare Limited
  • Amgen Inc.
  • APR Applied Pharma Research SA（Relief Therapeutics Holding AG）
  • AstraZeneca plc
  • Coherus BioSciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Ipsen SA
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-450A0628C601

The Cancer Supportive Care Drugs Market is projected to grow by USD 246.97 million at a CAGR of 7.00% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.79 million
Estimated Year [2026] USD 164.03 million
Forecast Year [2032] USD 246.97 million
CAGR (%) 7.00%

Cancer supportive care drugs are essential therapies used to prevent, reduce, or manage the adverse effects of cancer and its treatment, including chemotherapy, immunotherapy, radiation therapy, targeted therapy, and stem cell transplantation. These drugs address high-burden clinical needs such as chemotherapy-induced nausea and vomiting, cancer pain, neutropenia, anemia, infection risk, bone metastasis complications, mucositis, cachexia, thrombocytopenia, and treatment-related gastrointestinal or dermatologic toxicities. As oncology treatment becomes more personalized and increasingly intensive, supportive oncology has moved from an adjunct service to a core component of multidisciplinary cancer care. The clinical objective is no longer limited to symptom relief; it includes preserving dose intensity, reducing avoidable hospitalizations, improving adherence to anticancer regimens, enhancing patient-reported outcomes, and supporting quality of life across the cancer journey. Rising cancer incidence, aging populations, longer cancer survivorship, expanded access to systemic therapies, and broader adoption of immuno-oncology have increased the need for evidence-based supportive care pathways. Regulatory agencies, oncology societies, and health systems increasingly emphasize guideline-concordant symptom management, antimicrobial stewardship, opioid risk mitigation, biosimilar adoption, and real-world safety monitoring. These shifts are shaping demand for antiemetics, hematopoietic growth factors, analgesics, bone-modifying agents, iron therapies, corticosteroids, antibiotics, antifungals, antidiarrheals, appetite stimulants, and other supportive oncology medications. The competitive and clinical landscape is also being influenced by biosimilars, oral formulations, long-acting injectables, digital adherence tools, pharmacogenomics, and integrated palliative care models. For stakeholders across pharmaceutical development, oncology services, payers, and distribution networks, cancer supportive care drugs represent a strategically important category tied directly to cancer treatment continuity, patient safety, and health system efficiency.

Transformative Shifts in the Cancer Supportive Care Landscape

The cancer supportive care drugs landscape is undergoing structural change as oncology care shifts toward longer treatment durations, combination regimens, outpatient administration, and survivorship-focused management. Modern cancer therapies have altered toxicity profiles, creating new supportive care demands beyond traditional chemotherapy-associated complications. Immune checkpoint inhibitors can trigger immune-related adverse events requiring corticosteroids and immunosuppressive management, while targeted therapies and antibody-drug conjugates are associated with dermatologic, gastrointestinal, hematologic, ocular, and pulmonary toxicities that require proactive intervention. At the same time, conventional needs such as antiemetic protection, neutropenia prevention, cancer pain control, and bone health remain central to clinical practice. A major transformation is the increasing reliance on evidence-based clinical pathways aligned with recognized oncology supportive care guidelines. These pathways are standardizing the use of 5-HT3 receptor antagonists, NK1 receptor antagonists, colony-stimulating factors, erythropoiesis-stimulating agents where appropriate, bisphosphonates, RANK ligand inhibitors, and antimicrobial prophylaxis in defined risk settings. Another important shift is the expansion of biosimilars in supportive oncology, particularly for hematopoietic growth factors, which has improved formulary flexibility and intensified focus on cost-effective prescribing without compromising regulatory standards for safety, purity, and potency. Care delivery is also moving closer to the patient through ambulatory infusion centers, home-based oncology support, specialty pharmacy coordination, tele-oncology symptom triage, and oral oncology adherence programs. Payers and providers are increasingly measuring avoidable emergency visits, febrile neutropenia admissions, uncontrolled nausea, opioid-related safety events, and treatment discontinuation as indicators of supportive care performance. These transformations are encouraging drug developers to prioritize differentiated safety profiles, convenient dosing, compatibility with complex oncology regimens, and evidence that demonstrates measurable impact on treatment persistence and patient-centered outcomes.

Cumulative Impact of Artificial Intelligence on Supportive Oncology

Artificial intelligence is beginning to influence cancer supportive care drugs by improving risk prediction, toxicity surveillance, treatment personalization, and operational efficiency across oncology settings. AI-enabled models can analyze electronic health records, laboratory trends, treatment regimens, comorbidities, prior toxicities, genomics, and patient-reported outcomes to identify individuals at increased risk of febrile neutropenia, chemotherapy-induced nausea and vomiting, opioid complications, immune-related adverse events, malnutrition, dehydration, infection, or unplanned hospitalization. When validated and integrated responsibly, these tools can support earlier intervention with antiemetics, growth factors, analgesic optimization, antimicrobial prophylaxis, hydration support, or specialist referral. AI is also strengthening pharmacovigilance by detecting safety signals from real-world data, spontaneous adverse event reports, claims datasets, and clinical documentation. Natural language processing can capture symptoms that are often under-coded, such as fatigue, mucositis severity, appetite loss, neuropathic pain, and functional decline. In drug development, AI can assist with trial design, eligibility screening, toxicity clustering, biomarker exploration, and comparative effectiveness research for supportive oncology interventions. In clinical operations, predictive analytics can help infusion centers anticipate supportive medication needs, reduce treatment delays, optimize inventory, and coordinate specialty pharmacy dispensing. However, the cumulative impact of artificial intelligence depends on data quality, model transparency, equitable representation, clinician oversight, privacy protection, and alignment with regulatory expectations for software used in healthcare decision support. AI should not replace clinical judgment; rather, it can enhance precision supportive care by helping oncology teams identify risk earlier, standardize guideline-based interventions, and monitor outcomes continuously. As healthcare systems increasingly link reimbursement and quality measurement to symptom control and avoidable acute care utilization, AI-supported supportive oncology workflows are becoming a practical differentiator for high-performing cancer programs.

Key Regional Insights Across Cancer Supportive Care Drugs

Asia-Pacific is experiencing growing emphasis on cancer supportive care drugs as expanding oncology infrastructure, higher cancer detection, aging demographics, and wider access to systemic cancer therapies increase the need for antiemetics, hematopoietic growth factors, analgesics, bone-targeted therapies, antimicrobials, and nutritional support. The region is highly diverse: advanced health systems are accelerating protocol-driven supportive oncology and digital symptom monitoring, while emerging markets are focused on access, affordability, and essential medicine availability. North America has mature oncology treatment networks, extensive guideline adoption, strong specialty pharmacy capabilities, and established reimbursement mechanisms that support broad use of supportive care medicines, particularly in outpatient and community oncology settings. Clinical priorities include reducing chemotherapy-related hospitalizations, managing cancer pain safely, integrating palliative care earlier, and optimizing biosimilar use. Latin America is strengthening supportive cancer care through public oncology programs, private-sector treatment access, and regional cancer control initiatives, but variations in reimbursement, medicine availability, and diagnostic capacity continue to influence adoption patterns. In Europe, strong clinical guideline frameworks, pharmacovigilance systems, health technology assessment processes, and biosimilar policies shape supportive care prescribing, with increasing focus on value-based oncology, survivorship, and equitable access across countries. The Middle East is investing in oncology centers, national cancer strategies, and advanced treatment capabilities, increasing the importance of standardized supportive care protocols, pain management, infection prevention, and treatment adherence support. Across Africa, supportive oncology needs are significant due to rising cancer burden, late-stage diagnosis in many settings, constrained oncology workforce capacity, and gaps in access to essential medicines; priorities include strengthening palliative care, improving supply chains for pain relief and antiemetics, expanding infection management, and integrating supportive care into national cancer control plans. Across all regions, durable opportunities are tied to affordability, regulatory harmonization, clinician education, real-world evidence generation, and patient-centered delivery models.

Key Group Insights Across Global Healthcare Alliances

ASEAN countries are advancing cancer supportive care through expanding oncology services, public health insurance reforms, and regional efforts to improve access to essential cancer medicines, although disparities remain between urban cancer centers and underserved areas. Demand is closely linked to chemotherapy availability, supportive antiemetic protocols, infection prevention, pain relief, and affordability of biologic and biosimilar options. The GCC is characterized by substantial investment in specialist oncology infrastructure, health system modernization, and national cancer strategies, creating favorable conditions for protocol-based supportive care, advanced infusion services, and digital patient monitoring. The European Union places strong emphasis on medicine safety, pharmacovigilance, biosimilar confidence, health technology assessment, and cross-border policy coordination, making it a key environment for evidence-based supportive oncology adoption and access initiatives. BRICS countries combine large patient populations, expanding cancer treatment capacity, domestic pharmaceutical manufacturing capabilities, and significant access challenges, resulting in strong policy attention to affordability, local production, generic and biosimilar use, and essential medicine distribution. G7 countries generally have advanced oncology ecosystems, high adoption of clinical guidelines, robust regulatory oversight, and strong real-world evidence capabilities, supporting sophisticated use of supportive care drugs across chemotherapy, immunotherapy, radiation therapy, and survivorship settings. NATO member countries overlap substantially with high-income oncology systems in North America and Europe but also include varied reimbursement and procurement environments, making supply resilience, antimicrobial stewardship, and standardized emergency preparedness relevant to supportive oncology medicines. Across these groups, policy priorities increasingly converge around quality-of-life improvement, continuity of anticancer treatment, reduction of unplanned acute care, safe opioid and antimicrobial use, and cost-effective access to high-quality supportive care drugs.

Key Country Insights for Cancer Supportive Care Drugs

The United States has a highly developed supportive oncology environment shaped by clinical pathways, specialty pharmacy networks, payer utilization management, outpatient cancer care, biosimilar adoption, and strong emphasis on reducing avoidable emergency department use and hospital admissions. Canada prioritizes equitable access through provincial cancer systems, evidence-based formularies, palliative care integration, and supportive medication coverage decisions. Mexico is expanding oncology access while managing variability in public and private coverage, making affordability and reliable supply of antiemetics, analgesics, antibiotics, and growth factors central considerations. Brazil has significant oncology demand across public and private systems, with supportive care needs tied to chemotherapy access, pain management, infection control, and regional care disparities. The United Kingdom emphasizes guideline-led supportive oncology, early palliative care, medicine optimization, and systematic evaluation of clinical value within a publicly funded health system. Germany combines advanced oncology infrastructure, strong hospital and ambulatory care networks, and broad use of evidence-based supportive therapies, supported by rigorous regulatory and reimbursement standards. France places substantial focus on cancer care quality, pharmacovigilance, supportive care integration, and patient-centered oncology pathways. Russia faces supportive care requirements across a large geography, with policy attention on domestic production, oncology modernization, and access to essential cancer medicines. Italy and Spain maintain well-established oncology systems where supportive care is increasingly linked to survivorship, symptom control, biosimilar utilization, and regional reimbursement frameworks. China is rapidly expanding oncology capacity, improving drug access through regulatory reforms and reimbursement updates, and increasing the use of supportive care drugs alongside broader uptake of systemic cancer treatments. India has a large and diverse cancer care environment where affordability, generic availability, palliative care access, and urban-rural disparities strongly shape supportive oncology practice. Japan has advanced cancer treatment infrastructure, an aging population, and strong focus on antiemetic control, neutropenia prevention, pain management, and safety monitoring. Australia supports evidence-based supportive care through national cancer policies, reimbursement mechanisms, and integrated oncology services. South Korea combines advanced cancer screening, modern treatment centers, digital health capabilities, and strong clinical adoption of supportive therapies to improve treatment continuity and patient outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates how cancer supportive care drugs improve clinically meaningful outcomes, including reduced febrile neutropenia, lower rates of uncontrolled nausea and vomiting, fewer treatment delays, improved pain control, reduced skeletal-related complications, better adherence, and fewer unplanned acute care visits. Product strategies should emphasize differentiated tolerability, simplified dosing, compatibility with combination oncology regimens, and usability in outpatient, home-based, and specialty pharmacy models. Stakeholders should strengthen alignment with oncology clinical guidelines and invest in real-world evidence programs that capture patient-reported outcomes, medication persistence, hospitalization patterns, and safety signals across diverse populations. Access strategies should reflect regional differences in reimbursement, procurement, and essential medicine availability, with particular attention to affordable formulations, biosimilars, generics, and resilient supply chains. Partnerships with oncology providers should focus on protocol implementation, clinician education, nurse-led symptom management, pharmacist-supported medication review, and digital adherence tools. Companies and healthcare organizations should also prepare for artificial intelligence-enabled supportive care by ensuring data interoperability, ethical model validation, privacy compliance, and transparent clinical governance. For high-growth and access-constrained settings, the most impactful actions include improving availability of essential supportive medicines, supporting palliative care training, expanding cold-chain and distribution capabilities where needed, and generating local evidence that reflects real-world oncology practice. Across all markets, leaders should treat supportive care not as a secondary category but as a strategic pillar of cancer treatment quality, patient experience, and healthcare system efficiency.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources and cross-validation across authoritative healthcare references. The methodology emphasizes analysis of oncology clinical guidelines, regulatory agency publications, public health cancer control resources, peer-reviewed medical literature, pharmacovigilance frameworks, health technology assessment documentation, and recognized global health datasets related to cancer burden, treatment toxicity, access to medicines, and supportive oncology practices. The research process includes thematic mapping of major drug classes used in cancer supportive care, assessment of clinical use cases across chemotherapy, immunotherapy, radiation therapy, targeted therapy, and palliative care, and evaluation of regional policy and healthcare delivery dynamics. Insights are synthesized without relying on market sizing, market share, or forecasting. The analysis considers qualitative indicators such as guideline adoption, reimbursement structures, access barriers, biosimilar policy, clinical workflow integration, safety monitoring, and patient-centered outcome priorities. Regional, group, and country insights are interpreted through the lens of healthcare infrastructure, cancer treatment availability, regulatory maturity, medicine access, and evolving standards of care. To maintain reliability, claims are framed around established clinical and policy trends rather than speculative commercial projections. This approach supports an optimized but evidence-grounded view of cancer supportive care drugs for stakeholders seeking strategic clarity in a complex and rapidly evolving oncology ecosystem.

Conclusion

Cancer supportive care drugs are becoming increasingly central to oncology as health systems work to improve treatment tolerability, maintain anticancer therapy continuity, reduce preventable complications, and enhance quality of life for people living with cancer. The category spans a broad range of medicines that address nausea and vomiting, neutropenia, anemia, pain, infection, bone complications, nutritional decline, gastrointestinal toxicity, and immune-mediated adverse events. Transformative trends include guideline-based care pathways, biosimilar adoption, outpatient and home-based oncology support, real-world evidence generation, and the emerging use of artificial intelligence for predictive risk management and pharmacovigilance. Regional and country dynamics show that advanced oncology systems are refining supportive care through quality metrics and digital integration, while emerging and resource-constrained settings continue to prioritize access to essential supportive medicines, affordability, workforce training, and palliative care capacity. For industry leaders, success will depend on combining clinical credibility with practical access strategies, patient-centered evidence, resilient supply chains, and technology-enabled care coordination. As cancer treatment continues to evolve, supportive care drugs will remain indispensable to safer, more effective, and more humane oncology practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Supportive Care Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Antiemetics
    • 7.2.1. 5-HT3 Antagonists
    • 7.2.2. NK1 Antagonists
    • 7.2.3. Olanzapine
  • 7.3. Bone-Modifying Agents
    • 7.3.1. Bisphosphonates
    • 7.3.2. RANKL Inhibitors
  • 7.4. Hematopoietic Agents
    • 7.4.1. Erythropoiesis Stimulating Agents
      • 7.4.1.1. Darbepoetin
      • 7.4.1.2. Epoetin
    • 7.4.2. Myeloprotection Agents
    • 7.4.3. Thrombopoietin Receptor Agonists
  • 7.5. Pain Management Agents
    • 7.5.1. Non-Opioids
      • 7.5.1.1. Acetaminophen
      • 7.5.1.2. Adjuvant Analgesics
      • 7.5.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 7.5.2. Opioids

8. Cancer Supportive Care Drugs Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Hematologic Malignancies
    • 8.2.1. Leukemias
    • 8.2.2. Lymphomas
    • 8.2.3. Multiple Myeloma
    • 8.2.4. Myelodysplastic Syndromes
  • 8.3. Solid Tumors
    • 8.3.1. Breast Cancer
    • 8.3.2. Colorectal Cancer
    • 8.3.3. Gastrointestinal Cancers
    • 8.3.4. Head And Neck Cancer
    • 8.3.5. Lung Cancer
    • 8.3.6. Ovarian Cancer
    • 8.3.7. Prostate Cancer

9. Cancer Supportive Care Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Rectal
  • 9.5. Subcutaneous
  • 9.6. Topical
  • 9.7. Transdermal

10. Cancer Supportive Care Drugs Market, by Originator Type

  • 10.1. Introduction
  • 10.2. Biosimilar
  • 10.3. Branded
  • 10.4. Generic

11. Cancer Supportive Care Drugs Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Cancer Supportive Care Drugs Market, by Indication

  • 12.1. Introduction
  • 12.2. Bone Metastases Related Events
  • 12.3. Cachexia & Anorexia
  • 12.4. Cancer Pain
  • 12.5. Chemotherapy-Induced Nausea & Vomiting
    • 12.5.1. Acute CINV
    • 12.5.2. Breakthrough/Refractory CINV
    • 12.5.3. Delayed CINV
  • 12.6. Diarrhea
  • 12.7. Mucositis And Stomatitis
  • 12.8. Myelosuppression
    • 12.8.1. Chemotherapy-Induced Anemia
    • 12.8.2. Chemotherapy-Induced Neutropenia

13. Cancer Supportive Care Drugs Market, by Care Setting

  • 13.1. Introduction
  • 13.2. Inpatient
  • 13.3. Outpatient

14. Cancer Supportive Care Drugs Market, by Distribution Channel

  • 14.1. Introduction
  • 14.2. Hospital Pharmacies
  • 14.3. Mail-Order And Online Pharmacies
  • 14.4. Retail Pharmacies
  • 14.5. Specialty Pharmacies

15. Cancer Supportive Care Drugs Market, by End User

  • 15.1. Introduction
  • 15.2. Ambulatory Surgery Centers
  • 15.3. Homecare Settings
  • 15.4. Hospitals
  • 15.5. Oncology Clinics And Infusion Centers

16. Cancer Supportive Care Drugs Market, by Region

  • 16.1. Asia-Pacific
  • 16.2. North America
  • 16.3. Latin America
  • 16.4. Europe
  • 16.5. Middle East
  • 16.6. Africa

17. Cancer Supportive Care Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Cancer Supportive Care Drugs Market, by Country

  • 18.1. United States
  • 18.2. Germany
  • 18.3. China
  • 18.4. Japan
  • 18.5. India
  • 18.6. United Kingdom
  • 18.7. Canada
  • 18.8. Russia
  • 18.9. Brazil
  • 18.10. Italy
  • 18.11. Mexico
  • 18.12. France
  • 18.13. Spain
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2025
  • 19.2. FPNV Positioning Matrix, 2025
  • 19.3. Market Concentration Analysis, 2025
    • 19.3.1. Concentration Ratio (CR)
    • 19.3.2. Herfindahl Hirschman Index (HHI)
  • 19.4. Recent Developments & Impact Analysis, 2025
  • 19.5. Product Portfolio Analysis, 2025
  • 19.6. Benchmarking Analysis, 2025

20. Company Profiles

  • 20.1. Abbott Laboratories
  • 20.2. Acacia Pharma Group Plc
  • 20.3. Accord Healthcare Limited
  • 20.4. Amgen Inc.
  • 20.5. APR Applied Pharma Research S.A. by Relief Therapeutics Holding AG
  • 20.6. AstraZeneca plc
  • 20.7. Coherus BioSciences, Inc.
  • 20.8. Daiichi Sankyo Company, Limited
  • 20.9. Dr. Reddy's Laboratories Ltd.
  • 20.10. F. Hoffmann-La Roche Ltd.
  • 20.11. Fresenius Kabi AG
  • 20.12. Fresenius SE & Co. KGaA
  • 20.13. GlaxoSmithKline plc
  • 20.14. Helsinn Healthcare SA
  • 20.15. Heron Therapeutics, Inc.
  • 20.16. Ipsen S.A.
  • 20.17. Johnson & Johnson Services, Inc.
  • 20.18. Lupin Limited
  • 20.19. Novartis AG
  • 20.20. Pfizer Inc.
  • 20.21. Sanofi S.A.
  • 20.22. Teva Pharmaceutical Industries Ltd.
  • 20.23. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL 5-HT3 ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL 5-HT3 ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL 5-HT3 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NK1 ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NK1 ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NK1 ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OLANZAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OLANZAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OLANZAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BISPHOSPHONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BISPHOSPHONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BISPHOSPHONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RANKL INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RANKL INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RANKL INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOPOIETIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOPOIETIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOPOIETIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ERYTHROPOIESIS STIMULATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERYTHROPOIESIS STIMULATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ERYTHROPOIESIS STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DARBEPOETIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DARBEPOETIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DARBEPOETIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EPOETIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EPOETIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EPOETIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MYELOPROTECTION AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MYELOPROTECTION AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MYELOPROTECTION AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THROMBOPOIETIN RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THROMBOPOIETIN RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THROMBOPOIETIN RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAIN MANAGEMENT AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PAIN MANAGEMENT AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PAIN MANAGEMENT AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACETAMINOPHEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACETAMINOPHEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACETAMINOPHEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LEUKEMIAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LEUKEMIAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LEUKEMIAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LYMPHOMAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LYMPHOMAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LYMPHOMAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MYELODYSPLASTIC SYNDROMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MYELODYSPLASTIC SYNDROMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MYELODYSPLASTIC SYNDROMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL CANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL CANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL CANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEAD AND NECK CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HEAD AND NECK CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEAD AND NECK CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOSIMILAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOSIMILAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BONE METASTASES RELATED EVENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BONE METASTASES RELATED EVENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BONE METASTASES RELATED EVENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CACHEXIA & ANOREXIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CACHEXIA & ANOREXIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CACHEXIA & ANOREXIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA & VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA & VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA & VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACUTE CINV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ACUTE CINV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACUTE CINV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BREAKTHROUGH/REFRACTORY CINV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAKTHROUGH/REFRACTORY CINV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BREAKTHROUGH/REFRACTORY CINV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DELAYED CINV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DELAYED CINV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DELAYED CINV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DIARRHEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIARRHEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DIARRHEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MUCOSITIS AND STOMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL MUCOSITIS AND STOMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL MUCOSITIS AND STOMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL MYELOSUPPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL MYELOSUPPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL MYELOSUPPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CHEMOTHERAPY-INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL INPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL INPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL MAIL-ORDER AND ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL MAIL-ORDER AND ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL MAIL-ORDER AND ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ONCOLOGY CLINICS AND INFUSION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL ONCOLOGY CLINICS AND INFUSION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL ONCOLOGY CLINICS AND INFUSION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 326. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 327. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 328. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 329. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 346. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 347. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 348. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 349. ASEAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY C